Chemotherapy poses the highest risk for early menopause, particularly in women over 40, while radiation does not impact ...

Although racial disparities in the diagnosis and treatment of multiple myeloma remain, Black survivors of multiple myeloma ...

A dad had no idea that an incurable disease was 'eating away' at his bones, dismissing his symptoms as back pain. Then he ...

Inhibrx Biosciences’ antibody ozekibart has notched a key phase 2 win in a rare bone cancer that currently has no approved ...

Peripheral afferent neurons—nerves that send signals from all areas of the body to the central nervous system (brain and ...

Inhibrx Biosciences, Inc. reports strong phase 2 results for ozekibart in chondrosarcoma, with new cancer data and key ...

The experimental treatment, developed using cells at La Paz public hospital, achieves a preliminary survival rate of 70% in ...

Cancer therapies save lives but often cause neurologic damage, so we must recognize the full scope of neurotoxicity, from ...

Scientists from King's College London have successfully applied a new technology that disarms one of the most potent weapons ...

For patients living with CML, every diagnosis marks the start of a journey shaped by fear, resilience and, above all, hope.

According to study co-lead author Qizhi Qin, Ph.D., a postdoctoral fellow in the James Laboratory, the researchers also found ...